title: Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study.
abstract: The capability of molecular markers to differentiate between benign and malignant well-differentiated thyroid tumors remains unclear. The aim of this study was to evaluate the use of insulin-like growth factor II mRNA binding protein-3 (IMP3) mRNA expression to distinguish benign from malignant thyroid tumors. RNA samples from 80 formalin-fixed, paraffin-embedded thyroid tissues, including 22 usual papillary thyroid carcinomas (PTCs), 18 follicular variants of PTC, 5 follicular thyroid carcinomas, 33 follicular adenomas, and 2 hyperplastic nodules, were used for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. IMP3 mRNA expression levels in thyroid tumors were expressed as relative fold change (fold) after normalization with normal thyroid RNA. The results showed that thyroid carcinomas including PTC, follicular variants of PTC, and follicular thyroid carcinomas have significantly higher IMP3 expression levels with 48.3, 35.3, and 43.8 fold, respectively, compared with benign thyroid lesions (2.8 fold). Using the IMP3 expression value of 5 fold as a cutoff point to separate benign and malignant thyroid tumors, IMP3 qRT-PCR analysis had a 91.4% clinical specificity and 86.7% clinical sensitivity for the diagnosis of well-differentiated thyroid carcinomas. Conventional RT-PCR and immunohistochemical analysis for IMP3 in a subset of cases supported the qRT-PCR results. These results indicate that detection of IMP3 mRNA expression levels by qRT-PCR may be a useful molecular marker to assist in the diagnosis of well-differentiated thyroid carcinomas.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Long
authors.initials: L
authors.lastname: Jin
authors.forename: Amber R
authors.initials: AR
authors.lastname: Seys
authors.forename: Shuya
authors.initials: S
authors.lastname: Zhang
authors.forename: Michele R
authors.initials: MR
authors.lastname: Erickson-Johnson
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Roth
authors.forename: Barbara R
authors.initials: BR
authors.lastname: Evers
authors.forename: Andre M
authors.initials: AM
authors.lastname: Oliveira
authors.forename: Ricardo V
authors.initials: RV
authors.lastname: Lloyd
mesh_terms: D000236:Adenoma / Q000175:diagnosis*; D002277:Carcinoma / Q000175:diagnosis*; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D057089:Pathology, Molecular / Q000379:methods; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D016601:RNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000175:diagnosis*
chemical_list: C498780:IGF2BP3 protein, human; D012333:RNA, Messenger; D016601:RNA-Binding Proteins